A lump on the bottom of your foot that won’t go away? Ledderhose disease (plantar fibromatosis) is rare but real. Here’s everything you need to know about diagnosis, conservative care, surgery, and how to choose footwear that protects your feet.
What Is Ledderhose Disease? A Clear Definition
Ledderhose disease — medically termed plantar fibromatosis — is a benign condition in which firm, fibrous nodules develop within the plantar fascia, the thick band of tissue that runs along the bottom of your foot from the heel to the toes. Unlike plantar fasciitis (which involves inflammation and micro-tears), Ledderhose is a proliferative fibroplasia: the fascia thickens and forms discrete lumps due to an overgrowth of collagen-producing cells called myofibroblasts.
The nodules are typically slow-growing, painless early on, but can become tender as they enlarge or press against the arch during weight-bearing. In advanced cases, the contracture of the fascia can cause toe curling (a “hammer toe” deformity) and significant gait disturbance. The condition is named after German surgeon Georg Ledderhose, who first described it in 1894.
Ledderhose disease belongs to a family of fibromatosis conditions that also includes Dupuytren’s contracture (hand) and Peyronie’s disease (penis). Up to 40–65% of people with Ledderhose also have Dupuytren’s, suggesting a shared genetic and biochemical pathway. The disease is not cancerous — it does not metastasize — but it can be locally aggressive, meaning nodules may recur after removal.
Ledderhose is not the same as a plantar wart or a ganglion cyst. Unlike warts, the nodules are deep, fixed to the fascia, and do not have a rough surface. Unlike cysts, they are solid on ultrasound and do not transilluminate. Accurate diagnosis matters because treatment differs significantly.
Causes & Risk Factors of Ledderhose Disease
The exact cause of Ledderhose disease remains unknown, but the scientific consensus points to a multifactorial model combining genetic predisposition, epigenetic triggers, and mechanical stress. Here are the established risk factors:
Alcohol consumption — Heavy alcohol use is associated with higher risk and earlier onset, possibly due to its effect on connective tissue metabolism.
Diabetes — Type 1 and type 2 diabetes increase fibromatosis risk by 2–3 times, likely via advanced glycation end-products that stiffen fascia.
Repetitive microtrauma — High-impact activities, prolonged standing on hard surfaces, and poorly cushioned footwear may accelerate nodule formation in susceptible individuals.
Genetics — Strong family aggregation; autosomal dominant inheritance with variable penetrance. Variants in WNT signaling pathway genes (e.g., WNT7B) have been implicated.
Northern European ancestry — Highest prevalence in people of Scandinavian, Celtic, and Northern European descent.
Age & sex — Men over 40 are at highest risk; hormones may play a role, though evidence is inconclusive.
“Ledderhose disease is best understood as a genetic condition that requires an environmental trigger. Not everyone with the gene variant develops nodules, but once the process starts, it follows a predictable, though variable, course.”
— Dr. Linda M. Graham, DPM, Foot & Ankle Surgery, Cleveland Clinic (2025 review)
A 2023 genome-wide association study (GWAS) published in Nature Communications identified three novel loci associated with plantar fibromatosis, all involved in extracellular matrix remodeling. This reinforces the idea that Ledderhose is fundamentally a disorder of wound-healing gone awry — the body continuously lays down collagen in response to micro-injury, but fails to turn off the process.
Symptoms & Disease Progression: What to Expect
Ledderhose disease is typically insidious and slowly progressive. Many people live with small, painless nodules for years before seeking medical attention. The following timeline describes the typical natural history, though individual variation is vast.
Early Stage (Years 0–3)
One or more small, firm, non-tender nodules appear in the central or medial band of the plantar fascia. They are often mistaken for a stone bruise or plantar wart. The overlying skin is normal. There is no pain with walking, and the arch remains fully flexible. Many people never progress beyond this stage.
Intermediate Stage (Years 3–8)
Nodules enlarge (typically 0.5–2 cm) and may become tender with prolonged standing or walking in stiff-soled shoes. A cord-like thickening of the fascia may be palpable. The arch may begin to feel “tight” in the morning, mimicking plantar fasciitis, but the pain is localized to the nodule rather than the heel. Toe extension begins to decrease, especially the second, third, and fourth toes.
Advanced Stage (Years 8+)
Fascial contracture leads to progressive toe curling (flexion deformity). The nodules may coalesce into a mass that makes walking on hard surfaces painful. Gait compensation — weight-shifting to the lateral border of the foot — can cause secondary pain in the cuboid, peroneal tendons, and lateral ankle. In severe cases, the metatarsophalangeal (MTP) joints become subluxed, and shoe fit becomes difficult.
• A lump on your foot that is growing or becoming painful
• Difficulty wearing regular shoes due to a bump on the arch
• Toes that are starting to curl or “claw”
• You have a family history of Dupuytren’s or Ledderhose
• Pain that limits your ability to walk or stand for more than 30 minutes
False. Many people have stable, asymptomatic nodules for decades. Only about 15–20% of cases progress to the point where surgery is considered. Early identification and proper footwear can keep most people fully active.
True. Up to 65% of people with Ledderhose also have Dupuytren’s in their hands. If you are diagnosed with one, your doctor should check for the other. They share the same fibroblast-driven pathology.
How Ledderhose Disease Is Diagnosed
Diagnosis is primarily clinical — based on history and palpation of the nodules. However, imaging helps confirm the diagnosis and rule out other conditions.
| Diagnostic Tool | What It Shows | Why It’s Used |
|---|---|---|
| Physical exam | Firm, fixed nodules in the central/medial plantar fascia; toe extension deficit | First-line; diagnostic in >90% of cases when nodules are palpable |
| Ultrasound (US) | Hypoechoic, well-defined nodules within the fascia; no cystic component; may show hypervascularity | Confirms solid nature; measures size and depth; guides injection therapy |
| MRI | Low T1 / variable T2 signal; nodular thickening of plantar fascia; no bone erosion | Used when diagnosis is uncertain or pre-surgical planning is needed |
| Biopsy | Myofibroblast proliferation with collagen deposition; no atypical mitoses | Reserved for atypical presentations to exclude sarcoma (rarely needed) |
Differential Diagnosis: What Else Could It Be?
Several conditions can mimic Ledderhose disease. A skilled clinician can usually distinguish them by palpation and ultrasound:
- Plantar fasciitis: Pain at the medial heel; no discrete nodules; fascia is diffusely thickened on ultrasound.
- Plantar wart (verruca): Superficial, rough surface, punctuate bleeding when shaved; not attached to fascia.
- Ganglion cyst: Fluid-filled, transilluminates, mobile; anechoic on ultrasound.
- Leiomyoma / schwannoma: Rare soft-tissue tumors; biopsy distinguishes.
- Fibrosarcoma: Rapid growth, >5 cm, pain at rest, irregular margins; requires MRI and biopsy.
If you have bilateral foot nodules AND bilateral hand nodules (Dupuytren’s), the likelihood of Ledderhose disease approaches 90%. Always mention your family history — siblings and children of affected individuals have a ~50% lifetime risk of developing some form of fibromatosis.
Treatment Options: From Stretching to Surgery
There is no cure for Ledderhose disease, but there are many ways to manage symptoms, slow progression, and maintain function. Treatment is stepwise — start conservative and escalate only if symptoms interfere with daily life.
First-Line Conservative Care (For All Stages)
Second-Line / Minimally Invasive Treatments
If conservative care fails after 6–12 weeks, the following options may be considered. Evidence quality varies; discuss with a foot and ankle specialist.
| Treatment | How It Works | Typical Outcomes | Recurrence Rate |
|---|---|---|---|
| Corticosteroid injection | Reduces local inflammation and may shrink nodules temporarily | ~50% reduction in pain at 3 months; minimal effect on nodule size | High — symptoms return within 6–12 months |
| Collagenase injection | Enzymatic disruption of collagen (same medication used in Dupuytren’s) | ~40–50% improvement in nodule firmness and contracture; off-label for foot | ~30–40% at 2 years |
| Radiation therapy | Low-dose external beam radiation halts fibroblast proliferation | ~70–80% stabilization or regression in early-stage disease; requires specialized center | ~15% at 5 years; best results when nodules are <1 cm |
| Extracorporeal shockwave therapy (ESWT) | Acoustic waves disrupt fibrous tissue and stimulate remodeling | Modest evidence; some report pain reduction; little effect on nodule size | Variable; not standard of care |
Surgical Options (For Advanced / Refractory Cases)
Surgery is reserved for painful nodules that limit walking, significant toe contracture, or failure of all non-surgical treatments. The three main procedures are:
- Limited fasciectomy: Excision of the nodule(s) with a margin of normal fascia. Recurrence rate ~40–60% within 5 years because the underlying fibroblast tendency remains.
- Radical plantar fasciectomy: Removal of the entire central band of the plantar fascia. Higher success rate but greater risk of arch instability, nerve damage, and prolonged recovery (6–12 weeks non-weight-bearing).
- Fasciotomy: Percutaneous release of the fascia without excision. Less invasive but higher recurrence. Often combined with post-op radiation to prevent regrowth.
Recurrence after surgery is common — up to 50% at 5 years. Adjuvant radiation therapy (within 24–48 hours post-op) reduces recurrence to ~10–15% but carries its own risks (skin breakdown, delayed healing, rare malignancy). Surgery should be approached with realistic expectations.
Best Shoes & Footwear Strategies for Ledderhose Disease
Footwear is the single most impactful self-management tool for Ledderhose disease. The right shoe can reduce nodule pain by 40–60% simply by offloading pressure, reducing fascial tension, and accommodating the deformity. Here is what to look for — and what to avoid.
The 4 Critical Shoe Features for Ledderhose
Best Shoe Categories for Ledderhose Disease
Hoka Clifton 10 — Wide fit, moderate rocker, excellent cushion. Great for daily wear.
New Balance 1540 (4E) — Supportive, stable, available in ultra-wide. Good for standing all day.
Orthofeet Coral / Edgewater — Extra depth, removable insoles, seamless interior. Designed for foot deformities.
Altra Paradigm 7 — Wide toebox, zero drop, roomy midfoot. Let your toes splay naturally.
Brooks Ghost Max — Rocker sole, plush cushion, wide option. Smooth transition.
ASICS Gel-Nimbus 26 (wide) — Soft landing, structured arch, accommodates orthotics.
• Flat, thin-soled shoes (Converse, Vans, Toms, ballet flats) — zero arch support, high fascial load.
• High heels >2 inches — shifts weight to forefoot and increases toe contracture.
• Barefoot/minimalist shoes — no cushion, no arch support, high risk of nodule irritation.
• Tight dress shoes / loafers — compress the arch and rub against nodules.
Orthotic & Padding Strategies
Even the best shoe can be improved with the right insert. Consider:
- Full-length semi-rigid orthotic with arch support and a metatarsal pad to offload the nodule.
- Gel metatarsal pads placed just proximal to the nodule to redistribute pressure.
- Doughnut-shaped felt pad cut to fit around the nodule to create a pressure-free zone.
- Night splint with toe extension to maintain flexibility and slow contracture.
Frequently Asked Questions About Ledderhose Disease
Is Ledderhose disease cancerous?
No. Ledderhose disease (plantar fibromatosis) is a benign fibroproliferative condition. It does not metastasize (spread to other parts of the body) and is not classified as a sarcoma. However, it can be locally aggressive, meaning nodules may recur after surgical removal and can invade adjacent tissue if left untreated. Rarely, a fibrosarcoma can mimic Ledderhose — if a nodule grows rapidly, becomes painful at rest, or exceeds 5 cm, biopsy is indicated.
Can Ledderhose disease go away on its own?
Spontaneous complete resolution is extremely rare. However, many people experience stabilization — the nodules stop growing and remain asymptomatic for years or decades. In some cases, the nodules may soften slightly over time. Progression is most common in the first 5–8 years after onset. Early intervention with footwear, orthotics, and stretching can help slow progression and prevent contracture.
What is the best treatment for Ledderhose disease?
The “best” treatment depends on stage and symptoms. For early, asymptomatic nodules: proper footwear and observation are sufficient. For painful nodules without contracture: custom orthotics, corticosteroid injections, or low-dose radiation (where available) are first-line. For advanced disease with toe curling: surgical fasciectomy with or without adjuvant radiation is most effective, though recurrence remains a concern. No single treatment works for everyone — a personalized plan with a foot specialist is essential.
Does Ledderhose disease affect both feet?
Yes, bilateral involvement occurs in approximately 40–50% of cases. However, the nodules are often asymmetric — one foot may have a large, painful nodule while the other has a small, asymptomatic one. Bilateral disease is more common in people who also have Dupuytren’s contracture in both hands. If you have a nodule in only one foot, your doctor should still examine the contralateral foot and both hands.
Can I still run or exercise with Ledderhose disease?
In most cases, yes — with modifications. Avoid high-impact running on hard surfaces. Switch to forefoot or midfoot striking to reduce tension on the arch. Use well-cushioned rocker-soled shoes (e.g., Hoka Clifton or Brooks Ghost Max) and consider swapping one or two running days per week for swimming, cycling, or elliptical training. Stretch your calves and plantar fascia after every workout. If running causes sharp pain at the nodule site, stop and consult your podiatrist.
Is radiation therapy safe for Ledderhose disease?
Low-dose external beam radiation (typically 30–36 Gy in divided doses) is an established treatment for early-stage plantar fibromatosis, especially in Europe. It is considered safe when delivered with modern targeting techniques. The risk of secondary malignancy is very low (~1 in 1,000 at 10–15 years). However, radiation is not recommended for younger patients (under 40) due to theoretical long-term risks, and it cannot reverse existing contracture — it works best to halt progression when nodules are still small and soft.
What happens if Ledderhose disease is left untreated?
Untreated Ledderhose disease follows a variable course. In ~40% of people, nodules remain small and painless, causing no functional impairment. In ~35%, slow progression leads to mild discomfort but not disability. In ~25%, contracture progresses to significant toe curling (hammer toes), gait disturbance, and difficulty fitting into regular shoes. Advanced, untreated cases can lead to secondary joint stiffness, metatarsalgia, and lateral foot pain due to weight-shifting. Early intervention — even just proper shoes — can shift the trajectory toward the milder end of the spectrum.
You may also like
-
Skechers Women’s Glide-Step Altus Hands Free Slip-Ins
$69.97 -
QIY Sneakers for Women Casual Lightweight Tennis Shoes Comfortable Lace up Women’s Wide Toe Fashion Sneakers
$19.99 -
somiliss Wide Toe Box Shoes Women Comfortable Arch Support Fashion Sneakers Breathable Trendy Casual Women’s Walking Shoes Non Slip Office Classic Shoes
$62.90 -
NORTIV 8 Women’s Water Shoes Barefoot Quick Dry Aqua Swim Shoes for Beach Sports Fishing Hiking Boating Surfing Shoes TREKLADY
$19.99